Author

Joachim Albers

Merck KGaA, Darmstadt (Germany)ORCID 0000-0003-0582-1863Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alan D. D’AndreaiD· 1 shared Astrid ZimmermanniD· 1 shared Bose S. KochupurakkaliD· 1 shared Geoffrey Ira ShapiroiD· 1 shared Gregory Michael CoteiD· 1 shared Ian A. RoundtreeiD· 1 shared Jie HaoiD· 1 shared Kalindi ParmariD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan D. D’AndreaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintOct 28, 2026

DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy

Timothy B. Branigan, Roshen Alharthi, Bose S. Kochupurakkal…·Geoffrey Ira Shapiro

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

DOI 10.64898/2026.10.25.761677

humanexperimental assay

𝕏 PostBluesky